

Supplementary Table 5. The number of any cancer and each organ-specific cancer among valsartan new users before and after PSM

Cancer	PSM	Before			After 1:1:1 matching		
		Original (n = 1,726,619)	Eventually NDMA- uncontaminated (n = 392,548)	NDMA- contaminated (n = 461,599)	Original (n = 126,964)	Eventually NDMA- uncontaminated (n = 126,964)	NDMA- contaminated (n = 126,964)
Any cancer	Event	258,328	50,956	65,571	18,625	17,265	18,480
	Absolute risk	0.150	0.130	0.142	-	-	-
	IR (95% CI) ^{a)}	20.62 (20.54–20.70)	17.50 (17.35–17.65)	19.43 (19.28–19.58)	19.91 (19.63–20.20)	18.27 (18.00–18.54)	19.73 (19.44–20.01)
Bladder	Event	11,264	2,075	2,721	798	739	795
	Absolute risk	0.007	0.005	0.006	-	-	-
	IR (95% CI) ^{a)}	0.84 (0.83–0.86)	0.67 (0.65–0.70)	0.76 (0.73–0.79)	0.80 (0.75–0.86)	0.74 (0.69–0.79)	0.80 (0.74–0.85)
Breast	Event	9,269	1,697	2,119	573	540	535
	Absolute risk	0.012	0.010	0.010	-	-	-
	IR (95% CI) ^{a)}	1.51 (1.48–1.54)	1.26 (1.20–1.32)	1.24 (1.19–1.29)	1.44 (1.32–1.56)	1.35 (1.24–1.47)	1.34 (1.23–1.46)
Colorectal	Event	29,424	6,210	7,958	2,044	1,996	2,115
	Absolute risk	0.017	0.016	0.017	-	-	-
	IR (95% CI) ^{a)}	2.21 (2.19–2.24)	2.03 (1.98–2.08)	2.23 (2.18–2.28)	2.06 (1.97–2.15)	2.00 (1.92–2.09)	2.13 (2.04–2.22)
Gallbladder and etc.	Event	6,078	1,222	1,587	462	383	368
	Absolute risk	0.004	0.003	0.003	-	-	-
	IR (95% CI) ^{a)}	0.45 (0.44–0.47)	0.40 (0.38–0.42)	0.44 (0.42–0.46)	0.46 (0.42–0.51)	0.38 (0.34–0.42)	0.37 (0.33–0.41)
Kidney	Event	5,830	1,104	1,402	406	386	403
	Absolute risk	0.003	0.003	0.003	-	-	-
	IR (95% CI) ^{a)}	0.44 (0.42–0.45)	0.36 (0.34–0.38)	0.39 (0.37–0.41)	0.41 (0.37–0.45)	0.39 (0.35–0.43)	0.40 (0.37–0.44)
Liver	Event	34,582	7,084	8,419	2,507	2,394	2,340
	Absolute risk	0.020	0.018	0.018	-	-	-
	IR (95% CI) ^{a)}	2.60 (2.58–2.63)	2.32 (2.26–2.37)	2.36 (2.31–2.41)	2.53 (2.43–2.63)	2.41 (2.31–2.50)	2.36 (2.27–2.46)
Lung	Event	24,127	4,560	6,114	1,670	1,453	1,629
	Absolute risk	0.014	0.012	0.013	-	-	-
	IR (95% CI) ^{a)}	1.81 (1.79–1.83)	1.49 (1.44–1.53)	1.71 (1.67–1.75)	1.68 (1.60–1.76)	1.45 (1.38–1.53)	1.64 (1.56–1.72)
Pancreatic	Event	18,641	3,659	4,944	1,378	1,276	1,467
	Absolute risk	0.011	0.009	0.011	-	-	-
	IR (95% CI) ^{a)}	1.40 (1.38–1.42)	1.19 (1.15–1.23)	1.38 (1.34–1.42)	1.38 (1.31–1.46)	1.28 (1.21–1.35)	1.47 (1.40–1.55)
Prostate	Event	46,423	9,351	12,271	3,928	3,568	4,033
	Absolute risk	0.050	0.042	0.051	-	-	-
	IR (95% CI) ^{a)}	6.58 (6.52–6.64)	5.51 (5.40–5.62)	6.71 (6.59–6.83)	6.72 (6.51–6.93)	6.06 (5.87–6.27)	6.90 (6.69–7.12)
Stomach	Event	20,212	4,155	5,475	1,515	1,384	1,515
	Absolute risk	0.012	0.011	0.012	-	-	-
	IR (95% CI) ^{a)}	1.52 (1.50–1.54)	1.35 (1.31–1.40)	1.53 (1.49–1.57)	1.52 (1.45–1.60)	1.39 (1.31–1.46)	1.52 (1.45–1.60)
Thyroid	Event	16,554	3,221	4,003	1,204	1,170	1,208
	Absolute risk	0.010	0.008	0.009	-	-	-
	IR (95% CI) ^{a)}	1.24 (1.22–1.26)	1.05 (1.01–1.09)	1.12 (1.08–1.15)	1.21 (1.14–1.28)	1.17 (1.10–1.24)	1.21 (1.15–1.28)
Uterine	Event	3,262	663	828	195	203	192
	Absolute risk	0.004	0.004	0.004	-	-	-
	IR (95% CI) ^{a)}	0.53 (0.51–0.55)	0.49 (0.46–0.53)	0.48 (0.45–0.52)	0.49 (0.42–0.56)	0.50 (0.44–0.58)	0.48 (0.41–0.55)

PSM, propensity score matching; NDMA, N-Nitrosodimethylamine; IR, incidence rate; CI, confidence interval.

^{a)}Incidence rate per 1,000 person-years is calculated for each valsartan group and clinical outcome.